Androgen Receptor‐Immune Crosstalk in Metastatic Castration‐Resistant Prostate Cancer: From Context‐Dependent Remodeling to Biomarker‐Guided Translation
The Prostate · 2026-12 · 86 (16) · 1539-1555
DOI: 10.1002/pros.70254 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Prostate, online erschienen am 27.09.2026. Verfasst von Linjie Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen. Die Arbeit nennt 102 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, China, National Natural Science Foundation of China, Chongqing Science and Health Joint Project.
Abstract (Originalsprache)
Background
Metastatic castration‐resistant prostate cancer (mCRPC) rarely responds to immune checkpoint blockade despite clear evidence that androgen receptor (AR) signaling intersects with tumor immunity. The view that androgen deprivation uniformly enhances antitumor immunity does not explain the repeated failure of immunotherapy combinations in biomarker‐unselected populations.
Methods
This narrative review synthesizes mechanistic, translational, and clinical evidence and organizes it by cellular compartment, treatment‐associated immune state, clinical trial strategy, and biomarker readiness.
Results
AR‐directed therapy produces context‐dependent, compartment‐specific immune remodeling. It can alter tumor antigen visibility, thymic output, and T‐cell trafficking, while myeloid cytokines and metabolites, cancer‐associated fibroblasts, and metastatic niches sustain AR reactivation, T‐cell dysfunction, and immune exclusion. These effects are better understood as heterogeneous tumor‐immune states than as a fixed treatment window. Randomized phase III trials combining checkpoint blockade with AR pathway inhibitors, PARP inhibitors, or chemotherapy have not improved overall survival in unselected mCRPC, and dual‐checkpoint blockade has shown limited activity with substantial toxicity. Deficient mismatch repair or microsatellite instability‐high (dMMR/MSI‐H) disease is currently the only clinically validated enrichment factor for checkpoint blockade in mCRPC, although this subgroup is uncommon. Composite signatures remain investigational. CDK12, homologous‐recombination repair alterations, isolated tumor mutational burden‐high disease, PD‐L1, and AR‐V7 are not independently validated selection markers. T‐cell engagers have produced early PSA and radiographic responses by providing a distinct route to tumor‐T‐cell contact. Their development must balance this activity against cytokine‐release syndrome, antigen heterogeneity, variable therapeutic windows, and the lack of comparative evidence.
Conclusions
Progress requires trials that define the relevant tumor‐immune state, match treatment to the dominant resistance mechanism, and prospectively test biomarker‐treatment interaction. In current practice, dMMR/MSI‐H remains the only validated enrichment factor for checkpoint blockade in mCRPC; all other proposed markers and T‐cell engager strategies require prospective validation of treatment interaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Anatomy, Institute of Neuroscience, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
- Department of Psychosomatic Medicine, Zigong First People's Hospital, Zigong, China.
Förderung
- Natural Science Foundation of Chongqing, China
- National Natural Science Foundation of China
- Chongqing Science and Health Joint Project
- Senior Medical Talents Program of Chongqing for Young and Middle-aged Professionals
Zitieren
APA
Li, L., Feng, R., Zha, B., Yang, S., Wang, G., Jiang, Z., Mou, J., & Gao, F. (2026). Androgen Receptor‐Immune Crosstalk in Metastatic Castration‐Resistant Prostate Cancer: From Context‐Dependent Remodeling to Biomarker‐Guided Translation. The Prostate, 86(16), 1539-1555. https://doi.org/10.1002/pros.70254
Vancouver
Li L, Feng R, Zha B, Yang S, Wang G, Jiang Z, et al. Androgen Receptor‐Immune Crosstalk in Metastatic Castration‐Resistant Prostate Cancer: From Context‐Dependent Remodeling to Biomarker‐Guided Translation. The Prostate. 2026;86(16):1539-1555. doi:10.1002/pros.70254
BibTeX
@article{Li2026,
author = {Li, Linjie and Feng, Ruixi and Zha, Bingyang and Yang, Shiqi and Wang, Ge and Jiang, Zhijie and Mou, Jingsong and Gao, Fei},
title = {Androgen Receptor‐Immune Crosstalk in Metastatic Castration‐Resistant Prostate Cancer: From Context‐Dependent Remodeling to Biomarker‐Guided Translation},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {16},
pages = {1539--1555},
doi = {10.1002/pros.70254}
}
EUVIMED